The Effect of Esomeprazole and Fundoplication on Airways

The Effect of Esomeprazole and Nissen Fundoplication on Bronchial Responsiveness, Quality of Life, Exhaled Nitric Oxide and Pulmonary Function in Patients With Gastroesophageal Reflux Disease

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00994708

Enrollment

Unknown

Registered

2009-10-14

Start date

2004-12-31

Completion date

Unknown

Last updated

2009-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Airway Responsiveness

Brief summary

Evaluate the prevalence of bronchial responsiveness (BHR) among patients with gastroesophageal reflux disease (GERD). Investigate correlation between bronchial reactivity and the severity of GERD, and similarly investigate the correlation between exhaled nitric oxide (NO) and the severity of GERD. Compare the effects of esomeprazole 40 mg twice daily and Nissen fundoplication on bronchial reactivity, exhaled NO, pulmonary function and quality of life.

Interventions

DRUGesomeprazole

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Over 18 of age 2. Diagnosis of gastroesophageal reflux disease 3. Compliance to perform methacholine inhalation challenge (judged by the investigator)

Exclusion criteria

1. Known allergy to esomeprazole or any other PPI 2. Use of systemic corticosteroids within 3 weeks before any study visit 3. Pregnancy (in a written informed consent patients are asked to assure that they are not pregnant and they are also told to immediately stop the study medication if they become pregnant during the study) 4. Incapability to keep a 3-week washout with usual antireflux medication prior to the first visit 5. Regular use of PPI or H2-RA medication 3 months after fundoplication

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026